Biotech Company Receives SBIR Grant, Identifies Lead Compounds and Files Patent Application
Lexington,Kentucky and Queens, New York (PRWEB) October 02, 2014
Gismo Therapeutics Inc. is pleased to announce funding received to investigate therapeutics directed against a newly identified disease pathway in Alzheimer’s disease. A grant award from the Small Business Innovation Research (SBIR) Program, National Institute on Aging (NIA), National Institutes of Health (NIH) is entitled “Glycosaminoglycan Interacting Small Molecules (GISMO) as Novel AD Therapeutics.” The company also received a SBIR Matching Funds Grant from the Kentucky Cabinet for Economic Development, administered by the Kentucky Science and Technology Corporation.
“We are pleased to receive these grants as they will allow us to significantly advance our efforts to identify targeted oral therapeutics for the treatment of Alzheimer’s Disease. Our expertise is in small molecule compounds directed against glycosaminoglycans, which have been identified as key molecules that promote the spread of neurodegenerative diseases into unaffected neurons,” said Paul Gregor, Ph.D., founder of the company and inventor of the GISMO technology. “The company is making fine progress and we have now identified for the first time GISMO lead compounds with biological activity. The company has also recently filed a first patent application.”
Gismo Therapeutics Inc. is also pleased to announce a collaboration agreement with Dr. Michael P. Murphy, Associate Professor, Molecular and Cellular Biochemistry, Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky. Prof. Murphy, a recipient of several awards for research excellence and innovation, is an expert on in vitro and in vivo models of Alzheimer’s Disease.
About Gismo Therapeutics Inc.:
Gismo Therapeutics Inc. is a biotech start-up company targeting fundamental biochemical processes that are at the root of Alzheimer’s Disease pathogenesis. The company is developing its pioneering technology, GISMO, which is associated with a new hypothesis of the etiology of major neurodegenerative diseases. Gismo Therapeutics Inc. is developing first-in-class, disease modifying oral therapeutics for the treatment of Alzheimer’s Disease. Gismo Therapeutics Inc. was incorporated in 2011 in Delaware and has offices in Lexington, Kentucky and Queens, New York. The company is privately held and supported by grants and private funding. The company was founded by Paul Gregor, Ph.D., CEO, a graduate of the Weizmann Institute of Science (Rehovot, Israel). Its Board includes Dennis Choi, M.D., Ph.D., an award-winning neurologist, Chair of Department of Neurology and Director of Neuroscience Institute, Stony Brook University, New York.
For more information about Gismo Therapeutics Inc., visit the company’s recently launched website, http://gismotherapeutics.com
Dr. Rebecca Bernat
About Kentucky’s SBIR Match Program
Kentucky’s SBIR program matches all or part of federal SBIR awards received by Kentucky-based companies. It also provides a match to out-of-state companies, should they be willing to relocate to the Commonwealth. Since its inception in 2006, Kentucky’s program has awarded nearly $46.7 million to support 93 companies. A link to the online guidelines and application form for the Kentucky program are posted at http://www.ThinkKentucky.com/dci/SBIR
The permanent link to our press release: